Daily Cardiology Research Analysis
Three impactful cardiometabolic studies stood out today: a meta-analysis of randomized trials shows GLP-1–based therapies reduce incident atrial fibrillation in people with overweight/obesity; a Nature Communications analysis quantifies a dramatic global rise in metabolic syndrome to 1.54 billion adults; and mechanistic human tissue work reveals epicardial adipose tissue produces L-3-hydroxybutyrate in advanced heart failure, suggesting depot-specific cardiac fuel crosstalk.
Summary
Three impactful cardiometabolic studies stood out today: a meta-analysis of randomized trials shows GLP-1–based therapies reduce incident atrial fibrillation in people with overweight/obesity; a Nature Communications analysis quantifies a dramatic global rise in metabolic syndrome to 1.54 billion adults; and mechanistic human tissue work reveals epicardial adipose tissue produces L-3-hydroxybutyrate in advanced heart failure, suggesting depot-specific cardiac fuel crosstalk.
Research Themes
- GLP-1-based therapies reduce atrial fibrillation risk in obesity
- Global surge in metabolic syndrome and cardiometabolic risk
- Epicardial fat–heart metabolic crosstalk via L-3-hydroxybutyrate in heart failure
Selected Articles
1. Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials.
Across 24 randomized trials including 40,694 participants with overweight/obesity, GLP-1 receptor agonists and co-agonists reduced incident atrial fibrillation by 18% versus placebo. The benefit appears at least partially independent of the magnitude of weight loss, suggesting direct antiarrhythmic or cardiometabolic mechanisms.
Impact: Provides high-level evidence that GLP-1–based therapies may prevent AF in high-risk populations, bridging obesity and arrhythmia care. Supports reframing obesity pharmacotherapy as rhythm risk modification.
Clinical Implications: In patients with overweight/obesity at elevated AF risk (e.g., prior ablation, high atrial ectopy, structural heart disease), consider GLP-1–based therapies for both weight management and potential AF risk reduction alongside standard preventive strategies.
Key Findings
- Meta-analysis of 24 RCTs (n=40,694) showed an 18% relative reduction in incident AF with GLP-1RAs/co-agonists vs placebo (RR 0.82; 95% CI 0.70–0.96).
- The cardioprotective effect appears at least partly independent of weight-loss magnitude.
- Results support antiarrhythmic and cardiometabolic benefits of GLP-1–based therapies in overweight/obese populations.
Methodological Strengths
- Restricted to randomized controlled trials with random-effects meta-analytic synthesis
- Large aggregate sample size (n≈40,700) enhancing precision and generalizability
Limitations
- Heterogeneity in AF ascertainment and follow-up across trials; AF often a secondary outcome
- Limited data to fully disentangle weight-loss–independent mechanisms
Future Directions: Prospective RCTs with AF incidence as a primary endpoint and mechanistic biomarker substudies (electrophysiology, atrial remodeling, inflammation) to determine causal pathways and responder phenotypes.
BACKGROUND AND AIMS: Overweight and obesity represent major modifiable determinants of atrial fibrillation (AF) incidence and arrhythmia outcomes after AF ablation therapy. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their next-generation co-agonists exert potent weight-lowering and cardiometabolic effects and may therefore confer antiarrhythmic effects. This meta-analysis aimed to quantitatively assess the effect of GLP-1-based therapies on the risk of AF among individuals with overweight or obesity. METHODS: A systematic search of Medline, Scopus, and the Cochrane Library was conducted for randomized controlled trials (RCTs) through October 29, 2025. Data were analyzed using random-effects pairwise meta-analysis. RESULTS: Twenty-four RCTs encompassing 40,694 participants were included. Compared with placebo, treatment with GLP-1RAs or co-agonists resulted in a 18 % relative reduction in AF risk (Risk Ratio = 0.82; 95 % confidence interval, 0.70-0.96; P = 0.012; I CONCLUSIONS: Among individuals with overweight or obesity, GLP-1RAs and co-agonists were associated with a lower risk of incident AF event. This cardioprotective benefit may, at least in part, operate independently of the magnitude of weight loss.
2. Worldwide trends in metabolic syndrome from 2000 to 2023: a systematic review and modelling analysis.
Using 3,236 datasets covering 45.5 million adults, the authors estimated that global metabolic syndrome prevalence nearly doubled since 2000, reaching 31.0% in women and 25.7% in men by 2023 (≈1.54 billion adults). Burden rose with age, urbanization, and income, and increased in 196 countries, underscoring urgent cardiometabolic prevention needs.
Impact: Provides the most comprehensive and up-to-date global quantification of metabolic syndrome, informing health policy, resource allocation, and prevention strategies across cardiometabolic care.
Clinical Implications: Health systems should integrate MetS screening within primary care, prioritize high-risk groups (older, urban, higher-income settings), and scale evidence-based interventions (BP/lipid/glucose control, obesity pharmacotherapy, lifestyle) to curb downstream cardiovascular disease.
Key Findings
- Global MetS prevalence increased from 14.7% to 31.0% in women and 9.0% to 25.7% in men between 2000 and 2023.
- An estimated 1.54 billion adults had MetS in 2023, with increases observed in 196 countries/territories.
- Burden rises with age, urbanicity, and income; high SBP, high fasting glucose, and kidney dysfunction remain key risks; HALE gains reversed during the pandemic.
Methodological Strengths
- Large-scale synthesis of 3,236 data points encompassing 45.5 million adults across regions
- Bayesian modeling framework enabling harmonized estimates across heterogeneous sources and time
Limitations
- Heterogeneity in MetS definitions and measurement across studies and regions
- Data gaps in some countries and reliance on secondary sources may introduce uncertainty
Future Directions: Standardize MetS definitions and surveillance, expand primary data collection in underrepresented regions, and assess policy interventions’ impact on cardiometabolic outcomes.
Metabolic syndrome (MetS), a cluster of conditions including abdominal obesity, high blood pressure, and abnormal blood sugar and lipid levels, is a growing global health concern, yet its global burden remains poorly characterized. Here we show trends in MetS prevalence from 2000 to 2023, based on a systematic review and Bayesian modelling of 3236 data points with 45,549,151 adults. Between 2000 and 2023, prevalence rose from 14.7% (13.1-16.7) to 31.0% (28.5-33.9) among women, and from 9.0% (6.9-12.1) to 25.7% (21.5-31.1) among men. In 2023, an estimated 1.54 billion adults (1.35-1.76) had MetS globally: 846 million (776-924) women and 692 million (579-837) men. Prevalence increased with age, urbanicity, and income level, ranging from 7.5% to 45.0% among women and 6.5% to 59.6% among men across regions. Among both women and men, prevalence increased in 196 countries and territories. These findings call for targeted interventions to address the rising global burden.
3. Epicardial adipose tissue produces L-3-hydroxybutyrate in advanced heart failure: direct analysis of fat metabolic remodeling.
In 208 human participants spanning controls to severe HFrEF, metabolomics revealed depot-specific adipose remodeling. Epicardial adipose tissue exhibited impaired late-stage fatty acid oxidation and locally increased L-3-hydroxybutyrate production, suggesting a unique epicardial fat–heart metabolic axis in advanced heart failure.
Impact: Identifies a novel metabolic feature—L-3-hydroxybutyrate generation by epicardial fat—linking adipose remodeling to myocardial fuel supply, opening avenues for targeted metabolic modulation in heart failure.
Clinical Implications: Epicardial fat metabolism may influence myocardial energetics in advanced HFrEF; therapies modulating ketone metabolism or EAT function (e.g., metabolic agents, weight loss strategies) could be tailored with consideration of depot-specific effects.
Key Findings
- Metabolomics across EAT and SAT identified depot-specific remodeling with HF progression; EAT had impaired final steps of β-oxidation.
- EAT uniquely exhibited elevated 3-hydroxybutyrate and hydroxybutyrylcarnitine; ex vivo analyses showed increased L-3-hydroxybutyrate produced by EAT.
- Findings support a metabolic crosstalk between epicardial fat and the heart in advanced HFrEF.
Methodological Strengths
- Human tissue–based multi-omics profiling (>800 metabolites) across adipose depots with gene expression support
- Enantiomer-specific ex vivo analyses distinguishing L-3- vs D-3-hydroxybutyrate sources
Limitations
- Observational cross-sectional design limits causal inference and clinical endpoint linkage
- Generalisability may be limited (single-country cohorts); no interventional validation
Future Directions: Interventional studies targeting epicardial fat metabolism and ketone pathways; in vivo tracing of depot-derived metabolites to myocardium; correlation with clinical outcomes.
BACKGROUND: Heart failure (HF) progression involves complex metabolic and multi-organ alterations, but the specific adaptations in adipose tissue are not fully understood. AIMS: We aimed to characterize the metabolic remodeling of epicardial (EAT) and subcutaneous (SAT) adipose tissues in HF with reduced ejection fraction (HFrEF), focusing on lipid metabolism, fatty acid oxidation, and ketogenesis. METHODS: Clinical and metabolomic profiling were performed on metabolically stable controls (n = 34), patients with mild HFrEF (n = 45), and severe HFrEF (n = 129). Metabolomics profiling identified over 800 metabolites in EAT and SAT. Clustering and pathway enrichment analyses defined depot-specific metabolic shifts across HF stages, while gene expression analyses provided mechanistic support. RESULTS: Advancing HF was associated with declining cardiac function, systemic congestion, and a metabolic shift toward catabolism. Metabolomics revealed depot-specific adaptations: SAT transitioned smoothly to enhanced lipolysis, whereas EAT demonstrated impaired triacylglycerol replenishment and disrupted final turn of β-oxidation spiral. Both depots increased reliance on acylcarnitine degradation and lipolysis; however, EAT was uniquely characterized by late-stage impairment in mitochondrial and peroxisomal fatty acid oxidation, leading to elevation of 3-hydroxybutyrate and hydroxybutyrylcarnitine tissue levels. Ex vivo analyses of EAT explants showed significantly increased fraction of L-3-hydroxybutyrate enantiomer, produced by EAT, compared to D-3-hydroxybutyrate enantiomer originating from the liver. CONCLUSIONS: HF progression drives major, depot-specific metabolic remodeling in adipose tissue. In advanced HF, EAT shows impaired fatty acid oxidation and enhanced local production of L-3-hydroxybutyrate in the vicinity of myocardium, highlighting the close metabolic cooperation in nutrient supply between EAT and the heart muscle through the coronary circulation.